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Efficacy of DOTS strategy in 
treatment of respiratory 
tuberculosis in Gorgan, Islamic 
Republic of Iran 
A. Abassi1 and A.R Mansourian2 
ABSTRACT We carried out a follow-up cohort study of 260 smear-positive patients (178 on 
directly observed treatment, short-course (DOTS); 82 on non-DOTS] over a 2-year period 
to evaluate the efficacy of the DOTS strategy in treatment of tuberculosis (TB). All the 
patients had had cough for > 3 weeks; 91.9% had fever, 60.8% of them with sputum; and 
27.7% had a positive family history. The rate of treatment failure with DOTS was 9.0% at the 
end of the 2nd month and 1.7% at the beginning of the 5th month. In the control group 
these rates were 18.3% and 7.3% respectively. The DOTS strategy significantly increased the 
success rate of TB treatment (P < 0.05). 
Efficacité de la stratégie DOTS dans le traitement de la tuberculose pulmonaire à Gorgan en 
République Islamique d’Iran 
RÉSUMÉ Nous avons conduit une étude de cohorte portant sur 260 patients à frottis positif (178 
sous traitement de brève durée sous surveillance directe [DOTS, pour Directly Observed Treatment, 
Short-Course] et 82 sous traitement non-DOTS) sur une période de 2 ans afin d’évaluer l’efficacité de la 
stratégie DOTS dans le traitement de la tuberculose. Tous les patients toussaient depuis plus de 3 semaines, 
91,9 % d’entre eux étaient fébriles, 60,8 % présentaient des expectorations et 27,7 % une histoire familiale 
positive. Le taux d’échec thérapeutique sous DOTS était de 9,0 % à la fin du 2e mois de traitement et de 1,7 
% au début du 5e mois. Dans le groupe témoin, ces taux étaient respectivement de 18,3 % et de 7,3 %. La 
stratégie DOTS a entraîné une augmentation significative du taux de success thérapeutique du traitement 
antituberculeux (p < 0,05). 
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Introduction 
Tuberculosis (TB) is the most common
infectious disease worldwide, and causes
the death of about 2–3 million people each
year [1]. 
Incidence of TB has increased dramati­
cally recently and a high prevalence of
respiratory disease has been reported during
recent years [2]. These reports most com­
monly come from developing countries.
Factors involved in the increased number
of TB cases include poverty, immigration,
poor health facilities and drug abuse [3]. In
addition, irregular use of antituberculosis
drugs, incorrect dosage, poor knowledge
among general physicians, improper at­
tention of doctors, and drug resistance of
Mycobacterium tuberculosis can be fac­
tors in treatment failure [4]. Studies done
throughout the world show that by using the
directly observed treatment, short-course
(DOTS) strategy, the success rate of treat­
ment is about 90%–95%, or even greater
[5]. According to the same studies, even in
industrialized countries and among knowl­
edgeable and educated individuals at least
30% of patients, owing to a perception of
improvement, do not take their medication
properly and discontinue treatment after a
while. In the DOTS strategy, in addition
to direct observation of drug consumption,
having a standard regimen for treatment and 
follow-up of patients improves the success
rate. Conversely, for the reasons outlined
above, treatment regimens other than DOTS
have a low success rate, and may lead to
TB transmission in the community and
mycobacterial drug resistance [5]. 
Prevalence of TB in the Islamic Re­
public of Iran is about 39 per 100 000 [6]. 
Prevalence in Golestan province, where
this study was carried out, is quite high, the
second highest in the country [7]. 
The aim of this study was to evalu­
ate the efficacy of the DOTS strategy in
reducing the failure rate of TB treatment in
comparison with the conventional strategy.
The clinical and epidemiological features of
260 smear-positive respiratory TB patients
in Gorgan were studied for a period of 2
years. 
Methods 
We carried out a follow-up cohort study to
investigate the epidemiologic and clinical 
efficacy of DOTS strategy in treatment of
TB patients in residential areas of Gorgan:
a few areas classified as rural and one area
classified as urban. All new patients (hav­
ing had no prior treatment for TB) present­
ing to the health services during the period
1998–2000 whose respiratory specimens
were smear-positive were included in the
study. It should be noted that the rural area
in this study was immediately adjacent to
the urban area, therefore, the DOTS and the
non-DOTS groups were comparable.
All the new cases of TB in the patients
we studied had been diagnosed with sputum
smear-positive tests using the Ziehl–Nielsen
technique. The 178 patients in the rural ar­
eas were kept on the DOTS regimen (i.e. the
drugs were dispensed in the health centre
by a health worker, who observed the drugs
being taken) in accordance with the national
protocol (DOTS is obligatory in rural areas
but optional in urban areas). The 82 patients
in the urban areas (control group) were
treated using a non-DOTS strategy, i.e. the
same drug regimen was used and the drugs
were dispended in the health centres but pa­
tients consumed them at home; there was no
observation of their taking the medication.
All of the new TB cases underwent a 
6-month treatment regimen according to
ﳌﺍﺠﺔﻠﺍﻟﺼﺤﺔﻴﻟﻕﺮﺸ ﳌﺍﺘﻮﺳ،ﻂﻣﻈﻨﺔﻤﺍﻟﺼﺔﺤﺍﻟﻌﳌﺎﻴ،ﺔﺍﳌﺪﻠﺠﺍﻟﺜﺎﺚﻟ ﻋﺸ،ﺮﺍﻟﻌﺩﺪ ،٣ ٠٧٢٠
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the World Health Organization protocol: 2
months with 4 drugs (isoniazid, rifampin,
pyrazinamide, ethambutol) and 4 months
with 2 drugs (isoniazid, rifampin) [8]. In
the DOTS group, these drugs were given to
fasting patients by trained health workers
in 15 health centres every morning. In the
non-DOTS group, the drugs were taken by 
the patients themselves without any obser­
vation of consumption.
During the treatment period, sputum
samples were taken at the end of the 2nd
month and the beginning of the 5th month.
Patients who were smear-positive after the
2nd month had an extra month on the 4-drug 
regimen. Those smear-positive at the begin­
ning of the 5th month were considered treat­
ment failures. In these cases, drug resistance
was suspected and samples were sent to
the Tuberculosis and Respiratory Disease
Research Centre in Masih Daneshvari Hos­
pital, Tehran for further investigation.
Results were entered into SPSS, version
11, statistical software and analysed using 
2 and Fisher’s exact tests, with  P <  0.05  
considered statistically significant. Age,
sex, clinical manifestation, TB in the family
and also the treatment results (sputum smear
status after 2 months and at the beginning of
the 5th month) were recorded. 
Results 
A total of 260 smear-positive patients were
diagnosed during the study period. The clin­
ical manifestations of TB are presented in
Table 1. There were more females (51.5%)
than males. The largest age group was fe­
males aged 15–24 years. There were no
significant differences between the 2 groups
with regard to age, sex, socioeconomic sta­
tus or nationality. 
Of the 178 patients who were under
treatment using the DOTS strategy, 3 (1.7%)
Table 1 Observed clinical manifestation of 
tuberculosis in patients in Gorgan (1998 — 
2000) 
Clinical manifestation No. (n = 260) % 
Cough 260 100.0 
Fever 239 91.9 
Sputum 158 60.8 
Family history 72 27.7 
Haemoptysis 44 16.9 
were still smear-positive at the beginning of
the 5th month. Of the 82 patients who were
on the non-DOTS regimen, 6 (7.3%) were
still smear-positive at the beginning of the
5th month (Table 2).
In the DOTS group, 91.0% were smear-
negative at the end of the 2nd month and 
98.3% at the beginning of the 5th month.
In the non-DOTS (control) patients without
direct observation, the corresponding values
were 81.7% and 92.6% (P < 0.05). 
Discussion 
Through numerous studies and experience
in various situations, it is now widely ac­
cepted that the most important cause of fail­
ure in TB treatment programmes is irregular
drug-taking by patients, which is a direct
consequence of poor motivation [5]. A suc­
cessful, cost-effective, community-based
programme of directly observed therapy,
using volunteers, clinic staff and commu­
nity health workers or trained personnel can 
help ensure adherence to therapy [9]. 
This is the first report about the efficacy
of DOTS strategy in Golestan province in 
the Islamic Republic of Iran. The rate of
negative smears at the beginning of the 5th 
month is an excellent index for evaluating
the efficacy of TB treatment. Treatment
ﳌﺍﺠﺔﻠﺍﻟﺼﺤﺔﻴﻟﻕﺮﺸ ﳌﺍﺘﻮﺳ،ﻂﻣﻈﻨﺔﻤﺍﻟﺼﺔﺤﺍﻟﻌﳌﺎﻴ،ﺔﺍﳌﺪﻠﺠﺍﻟﺜﺎﺚﻟ ﻋﺸ،ﺮﺍﻟﻌﺩﺪ ،٣ ٠٧٢٠
Table 2 Comparison of treatment failure rate in patients on the DOTS and 
the non-DOTS regimens 
Treatment 
regimen 
   
   
End of 2nd month 
Treatment Conversion 
failure   rate
No.         % No.         
               
% 
Beginning of 5th montha
Treatment Conversion 
    failure rate 
No.        %       No.         % 
 Total 
DOTS 
Non-DOTS 
16 
15 
9.0 
18.3        
162 
67 
91.6 
81.7 
3         
6         
1.7       
7.3        
175      
76       
98.3 
92.7 
       
        
178 
82 
aP < 0.05, Fisher exact test. 
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failure in patients on the DOTS strategy was
much lower than in the non-DOTS group.
This correlates well with the results of stud­
ies done in other Asian countries [10–15]. 
In a study in China with a large sample
population the treatment failure rate in pa­
tients under the DOTS strategy was 6.2%
[12]; in our study we had better results with
patients on the DOTS strategy.
In Iraq treatment failure in patients un­
der the DOTS strategy was 2.0% and in the
control group it was 5.8%, which is agree­
ment with our findings, and emphasizes the
importance of the DOTS strategy [14]. Mu­
rali and Udaya also reported a lower treat­
ment failure rate among DOTS patients, 9%
compared to 47% in the non-DOTS group,
although the failure rate in our study was
lower than theirs [15]. 
Although these differences were not
statistically significant, there is a basis for
further investigation. In our study, the high­
est rate of infection was among the younger
age group, 15–24 years; in a study done
in Canada, the highest rate of infection
was in those > 65 years [16]. Given that in
industrialized countries TB is mostly the
reactivated form of primary infection [17], 
the high prevalence in older age groups may
be a result of weaker immunity in those
patients. All the patients in our study were,
however, new TB cases.
The clinical syndrome in this study (spu­
tum, cough, fever, haemoptysis) had a good
correlation with a previous study [18]. The
most common clinical manifestation was
cough, which was also found in other stud­
ies [13,15,16]. 
In accord with those of other investiga­
tions, the findings of this study demonstrate
the effectiveness of the DOTS strategy
in treatment of TB patients. Considering
conversion rates, our study showed a better
efficacy in the DOTS group compared to
some studies from other countries, such as a
study in India which showed a 90% success
rate with the DOTS strategy compared to
81% for the control patients [11]; in a study
done in Iraq, the treatment success rate with 
the DOTS strategy was 96.2% but 76.2% in
the control group [13]. 
In 27.7% of cases there was a positive
family history of TB. This agrees with the
findings of a study from Masih Daneshvari
teaching hospital in Tehran (26.9%) [18].
Therefore, family members of infected pa­
tients also need to be checked. In a study
in Pakistan it was reported that only 8.5%
of family members of TB patients had the
disease itself. It is nevertheless an important
point to be taken into consideration when 
managing TB patients [19]. 
Recommendations 
The DOTS strategy is an excellent way 
to reduce treatment failure, therefore, the
ﳌﺍﺠﺔﻠﺍﻟﺼﺤﺔﻴﻟﻕﺮﺸ ﳌﺍﺘﻮﺳ،ﻂﻣﻈﻨﺔﻤﺍﻟﺼﺔﺤﺍﻟﻌﳌﺎﻴ،ﺔﺍﳌﺪﻠﺠﺍﻟﺜﺎﺚﻟ ﻋﺸ،ﺮﺍﻟﻌﺩﺪ ،٣ ٠٧٢٠
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health system authorities in our country
should make every effort to get the coopera­
tion of all the relevant organizations (both
private and public sector) to implement
the DOTS strategy suggested by the World
Health Organization. It is also a safe and
effective way of controlling and prevent­
ing multidrug resistance in Mycobacterium 
tuberculosis. 
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Global tuberculosis control: surveillance, planning, financing. WHO
Report 2007 
The eleventh report in this series charts progress towards the Mil­
lennium Development Goals (MDGs) as related to tuberculosis (TB).
Focusing on five key indicators – case detection, treatment success,
incidence, prevalence and deaths – Global tuberculosis control: sur­
veillance, planning, financing presents the fullest possible assessment
of progress towards MDG targets in the world as a whole, and in each 
WHO region and country. 
The report compiles case notifications and treatment outcomes for
200 countries up to the end of 2005. It also investigates how ef­
fectively national TB control programmes have begun to implement
WHO's expanded Stop TB Strategy, and sets out costs, budgets, ex­
penditures and sources of funding. The report summarizes progress
on initiatives, including the development of public–private partner-
ships in TB control, human resources development, the management
of drug-resistant TB, and collaborations in TB and HIV/AIDS control. 
Further information about this and other WHO publications is available
at: http://www.who.int/publications/en/
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